United Therapeutics Corporation (UTHR) Net Profit Margin: 40.61%
Is United Therapeutics Corporation’s net profit margin high or low?
United Therapeutics Corporation's net profit margin of 40.61% is in line with its 5-year average of 37.71%, near the high end of its 5-year range (28.23%–42.31%).
As of Saturday, June 13, 2026. 2.70% below its 12-month average of 41.73%.
UTHR Net Profit Margin Chart
UTHR Average Net Profit Margin Chart
UTHR Current vs Average Net Profit Margin Chart
UTHR Net Profit Margin Metrics
NET PROFIT MARGIN
40.61%
NET PROFIT MARGIN AVG TTM
41.73%
NET PROFIT MARGIN AVG 3Y
40.84%
NET PROFIT MARGIN AVG 5Y
37.71%
NET PROFIT MARGIN AVG 10Y
33.51%
NET PROFIT MARGIN AVG 15Y
30.67%
NET PROFIT MARGIN AVG 20Y
28.22%
CURRENT VS TTM AVG
-2.70%
CURRENT VS 3Y AVG
-0.55%
CURRENT VS 5Y AVG
+7.68%
CURRENT VS 10Y AVG
+21.19%
CURRENT VS 15Y AVG
+32.41%
CURRENT VS 20Y AVG
+43.91%
UTHR Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | $23.17B | 40.61% | 41.73% | 40.84% | 37.71% |
| Waters Corporation (WAT) | $23.17B | 11.91% | 20.93% | 21.85% | 22.39% |
| BioNTech SE (BNTX) | $22.90B | -44.73% | -31.89% | 3.77% | 12.08% |
| Mettler-Toledo International Inc. (MTD) | $22.86B | 21.40% | 21.94% | 21.74% | 21.20% |
| Labcorp Holdings Inc. (LH) | $21.83B | 6.66% | 6.01% | 6.56% | 9.24% |
| Veeva Systems Inc. (VEEV) | $25.92B | 28.37% | 27.22% | 24.83% | 24.72% |
| Moderna, Inc. (MRNA) | $19.80B | -143.55% | -128.24% | -70.25% | -50.87% |
| DexCom, Inc. (DXCM) | $29.08B | 19.31% | 16.12% | 14.73% | 15.57% |
| Hologic, Inc. (HOLX) | $16.97B | 13.18% | 16.70% | 17.87% | 22.37% |
| Biogen Inc. (BIIB) | $29.53B | 13.92% | 15.03% | 17.95% | 19.29% |
Margin Comparison
Operating Margin
45.3%
Net Profit Margin
40.6%
United Therapeutics Corporation Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
United Therapeutics Corporation Net Profit Margin FAQ
- What is the net profit margin for United Therapeutics Corporation (UTHR)?
- The net profit margin for UTHR stock is 40.61%.
- Is United Therapeutics Corporation's net profit margin high or low?
- United Therapeutics Corporation's net profit margin of 40.61% is in line with its 5-year average of 37.71%, near the high end of its 5-year range (28.23%–42.31%).
- What is the TTM average net profit margin for United Therapeutics Corporation (UTHR)?
- The TTM average net profit margin for UTHR stock is 41.73%.
- What is the 3Y average net profit margin for United Therapeutics Corporation (UTHR)?
- The 3Y average net profit margin for UTHR stock is 40.84%.
- What is the 5Y average net profit margin for United Therapeutics Corporation (UTHR)?
- The 5Y average net profit margin for UTHR stock is 37.71%.
- What is the 10Y average net profit margin for United Therapeutics Corporation (UTHR)?
- The 10Y average net profit margin for UTHR stock is 33.51%.
- What is the 15Y average net profit margin for United Therapeutics Corporation (UTHR)?
- The 15Y average net profit margin for UTHR stock is 30.67%.
- What is the 20Y average net profit margin for United Therapeutics Corporation (UTHR)?
- The 20Y average net profit margin for UTHR stock is 28.22%.
United Therapeutics Corporation Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 41.94% |
| 2024-12-31 | 41.53% |
| 2023-12-31 | 42.31% |
| 2022-12-31 | 37.56% |
| 2021-12-31 | 28.23% |
| 2020-12-31 | 34.71% |
| 2019-12-31 | -7.21% |
| 2018-12-31 | 36.20% |
| 2017-12-31 | 24.22% |
| 2016-12-31 | 44.64% |
| 2015-12-31 | 44.46% |
| 2014-12-31 | 26.39% |
| 2013-12-31 | 15.63% |
| 2012-12-31 | 33.23% |
| 2011-12-31 | 29.32% |
| 2010-12-31 | 17.54% |
| 2009-12-31 | 5.26% |
| 2008-12-31 | -15.20% |
| 2007-12-31 | 9.41% |
| 2006-12-31 | 46.33% |
| 2005-12-31 | 56.09% |
| 2004-12-31 | 20.99% |
| 2003-12-31 | -18.69% |
| 2002-12-31 | -78.52% |
| 2001-12-31 | -650.55% |
| 2000-12-31 | -3689.55% |
| 1999-12-31 | -8375.00% |
| 1998-12-31 | -12800.00% |
Related Metrics
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martine A. Rothblatt